NCT07430280Not yet recruiting
Synbiotic Supplementation and Inflammation in Predialysis Chronic Kidney Disease
Effect of a Synbiotic Containing Lactobacillus Rhamnosus, Bifidobacterium Longum, and Agave Fructans on High-Sensitivity C-Reactive Protein Levels in Patients With Predialysis Chronic Kidney Disease: A Double-Blind, Placebo-Controlled Trial
Source: ClinicalTrials.gov · Last updated 27 Feb 2026
Brief summary (registry, in English)
Chronic kidney disease (CKD) is a long-term condition in which the kidneys gradually lose their ability to function properly. People with chronic kidney disease (CKD) often experience chronic inflammation and digestive symptoms that may affect their quality of life. This study aims to evaluate whether daily supplementation with a synbiotic (a combination of probiotics and prebiotics) can reduce inflammation and improve gastrointestinal symptoms in adults with chronic kidney disease (CKD) stages 3 to 5 who are not receiving dialysis. Participants will be randomly assigned to receive either a synbiotic containing Lactobacillus rhamnosus, Bifidobacterium longum, and agave fructans, or a placebo, for a total of 16 weeks. Blood tests will be performed to measure inflammation, and participants will complete questionnaires related to digestive symptoms, quality of life, and dietary habits. The information obtained from this study may help improve nutritional strategies and supportive care for people living with chronic kidney disease.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- First submitted
- 18 Feb 2026
- Start date
- 1 Mar 2026
- Primary completion date
- 1 Mar 2026
- Lead sponsor
- Centenario Hospital Miguel Hidalgo
- Diseases
- Chronic kidney disease
- NCT number
- NCT07430280
What you commit to
- Study type: Interventional
- Planned participants: 100
- From 1 Mar 2026 to the primary completion date, 1 Mar 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current renal replacement therapy (hemodialysis or peritoneal dialysis).
- Use of antibiotics, probiotics, prebiotics, or synbiotics within 4 weeks prior to enrollment.
Other illness
- Active infection, inflammatory disease, or malignancy.
- Known intolerance or allergy to components of the synbiotic or placebo.
Other
- Acute kidney injury.
- Pregnancy or breastfeeding
Who the study is looking for
- Adults aged 18 to 80 years.
- Diagnosis of chronic kidney disease in pre-dialysis stages.
- Stable clinical condition for at least 3 months prior to enrollment.
- Ability to provide written informed consent.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.